A Phase 2 interventional study of Paclitaxel in Esophageal Cancer, sponsored by Bristol-Myers Squibb. Completed. Per ClinicalTrials.gov, last updated 2013-07-26.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing paclitaxel in Esophageal Neoplasms — 11 open to participants now, 18 under way, none of them phase 3. Paclitaxel · Esophageal Neoplasms.
Among the 80 studies testing paclitaxel in Esophageal Neoplasms, this one is the 70th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2008, is one of 48 in phase 2, and was the 34th registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.
Browse Esophageal Neoplasms studies →11 of the 80 studies testing paclitaxel in Esophageal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Peking University Cancer Hospital & Institute · Sites in China
Ages 18–75
Merck Sharp & Dohme LLC · Sites in United States, Brazil, Chile and 8 more countries
Ages 18+
Fujian Medical University Union Hospital · Sites in China
Ages 18–75
Sichuan University · Sites in China
Ages 70–100
National University Hospital, Singapore · Sites in Singapore
Ages 21–99
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 60 · Phase 3 13 · Phase 4 1
First in 1995; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 58 across 1,347 interventional studies indexed under Esophageal Neoplasms.
Median enrollment 40 across the 74 interventional studies. Of the 41 that completed or were terminated, 11 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 80 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 7 studies filed under Esophageal Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing paclitaxel in Esophageal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183126University of Michigan Rogel Cancer CenterPharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | 2026-11 |
| NCT02213497Abramson Cancer Center at Penn MedicineDose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer | 2026-12-31 |
| NCT06601309Fujian Medical University Union HospitalBiomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC | 2027-03-31 |
| NCT02297217AHS Cancer Control AlbertaChemoradiotherapy for Advanced Esophageal Cancer | 2027-04-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 80 studies testing paclitaxel in Esophageal Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced or recurrent esophageal cancer who have completed the previous Phase 2 study (CA139-540) and who should continue on therapy with paclitaxel as assessed by the treating investigator(s). To evaluate the severity of observed adverse reactions in treated subjects for assessment of long-term safety.
Subjects with advanced or recurrent esophageal cancer who have completed the previous late Phase 2 study (CA139-540) and for who continued therapy with paclitaxel would be beneficial as deemed by the investigator(s).
One hour intravenous infusion on Days 1, 8, 15, 22, 29, 36, followed by 1 week of rest (6 weeks on, 1 week off). One treatment course consists of 49 days. Day 1 dose same level as last dose of original Study CA139-540 (100mg/m2, 80 mg/m2, or 60 mg/m2). Treatment to continue until disease progression or unacceptable toxicity apparent.
Drug: Paclitaxel
Also known as: Taxol, BMS-181339
Number of Adverse Events (AEs) Per Participant
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Severity of the adverse event was judged and graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0.
Time frame: Weekly Day 1 to 4 years
Number of Participants With Complete Response to Tumor
Tumor measured/evaluated via imaging and assessed according to the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.0 wherein complete response is disappearance of all target lesions; partial response is 30% decrease in the sum of the longest diameter of target lesions; progressive disease is 20% increase in the sum of the longest diameter of target lesions, and stable disease is small changes that do not meet above criteria. The baseline assessment was done prior to the first administration of drug in the original Study CA139-540 (NCT 00344552).
Time frame: Every 7 weeks Day 1 to 4 years
Original Study CA139-540 (NCT 00344552) at Dr. K. Kato National Cancer Center Hospital in Tokyo, Japan, closed in 2008 and one participant rolled over into Study CA139-557.
| Milestone | Paclitaxel |
|---|---|
| Started | 1 |
| Completed | 1 |
| Not completed | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Severity of the adverse event was judged and graded according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0.
| adverse events | Paclitaxel |
|---|---|
| Number of Adverse Events (AEs) Per Participant | 32 |
Tumor measured/evaluated via imaging and assessed according to the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.0 wherein complete response is disappearance of all target lesions; partial response is 30% decrease in the sum of the longest diameter of target lesions; progressive disease is 20% increase in the sum of the longest diameter of target lesions, and stable disease is small changes that do not meet above criteria. The baseline assessment was done prior to the first administration of drug in the original Study CA139-540 (NCT 00344552).
| participants | Paclitaxel |
|---|---|
| Number of Participants With Complete Response to Tumor | 1 |
Collected over 4 years (4 March 2008 to 24 March 2012). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paclitaxel | — | 0/1 (0%) | 1/1 (100%) |
| Event | Paclitaxel |
|---|---|
| neutrophil count decreaseInvestigations | 1/1 |
| alopeciaSkin and subcutaneous tissue disorders | 1/1 |
| back painMusculoskeletal and connective tissue disorders | 1/1 |
| blood pressure increasedInvestigations | 1/1 |
| chillsGeneral disorders | 1/1 |
| contusionInjury, poisoning and procedural complications | 1/1 |
| coughRespiratory, thoracic and mediastinal disorders | 1/1 |
| cystitisInfections and infestations | 1/1 |
| decreased appetiteMetabolism and nutrition disorders | 1/1 |
| dizzinessNervous system disorders | 1/1 |
| Age, Categorical(Participants) | Paclitaxel |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 1 |
| >=65 years | 0 |
| Age Continuous(years) | Paclitaxel |
|---|---|
| Mean | 47 ± NA |
| Sex: Female, Male(Participants) | Paclitaxel |
|---|---|
| Female | 1 |
| Male | 0 |
| Region of Enrollment(participants) | Paclitaxel |
|---|---|
| Japan | 1 |
No study locations are listed for this record.
The record gives a start of Mar 2008, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paclitaxel